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ABSTRACT 
Our previous work involved the development of a recombinant fowlpox virus encoding 
survivin (FP-surv) vaccine that was evaluated for efficacy in mesothelioma mouse 
models. Results showed that FP-surv vaccination generated significant immune 
responses, which led to delayed tumor growth and improved animal survival. We have 
extended those previous findings in the current study, which involves the pre-clinical 
development of an optimized version of FP-surv designed for human immunization 
(HIvax). Survivin-derived peptides for the most common haplotypes in the human 
population were identified and their immunogenicity confirmed in co-culture experiments 
using dendritic cells and T cells isolated from healthy donors. Peptides confirmed to 
induce CD8+ and CD4+ T cells activation in humans were then included in 2 transgenes 
optimized for presentation of processed peptides on MHC-I (HIvax1) and MHC-II 
(HIvax2). Fowlpox vectors expressing the HIvax transgenes were then generated and 
their efficacy was evaluated with subsequent co-culture experiments to measure 
interferon- and granzyme B secretion. In these experiments, both antigen specific 
CD4+ and CD8+ T cells were activated by HIvax vaccines with resultant cytotoxic activity 
against survivin-overexpressing mesothelioma cancer cells. These results provide a 
rationale for clinical testing of HIvax1 and HIvax2 vaccines in patients with survivin-
expressing cancers.  
Keywords: mesothelioma, cancer vaccines, fowlpox, T-Lymphocytes, immunodominant 
epitopes, EpiMatrix, tregitopes. 
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INTRODUCTION 
Despite recent progress in surgical, chemotherapeutic, and radiotherapy approaches, 
several cancers are still difficult to treat and cure, especially in patients with advanced 
stages of the disease. Therefore, new therapeutic strategies are needed and 
immunotherapeutic approaches targeting tumor-associated antigens (TAAs) are among 
the most prominent approaches recently developed. CD8+ cytotoxic T lymphocytes 
(CTLs) are the most important effector cells for antitumor immune responses. CTLs 
recognize TAA-derived peptides that are presented on the tumor cell surface in 
association with major histocompatibility complex (MHC) class I molecules, leading to 
tumor cell killing.1 CD4+ T helpers (Th) cells provide assistance to CTLs in the form of 
soluble mediators like cytokines, which enhance the CTL expansion and cytolytic 
function.2 Initial activation of naïve antigen-specific lymphocytes is mediated by 
specialized MHC-positive cells, particularly dendritic cells (DC). Clinical evidence for the 
effectiveness of antitumor immune responses has been obtained in several clinical 
settings.3-5  
Survivin has been shown to fulfill major criteria for prime target antigens included in 
broad applicable anti-cancer vaccines: 1) tumor cells depend on its actions for survival 
or proliferation, 2) expression is strong in multiple tumor types but rarely detectable in 
normal tissues, 3) immunogenicity has been demonstrated in patients with different 
cancers, and 4) peptides restricted by different HLA molecules are known. Survivin is 
expressed in a majority of tumor cells at all stages, from premalignant to metastatic 
lesions, in solid tumors and hematopoietic malignancies, and the gene encoding 
survivin is the fourth most abundantly expressed gene in melanomas and cancers of the 
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colon, lung, brain, and breast. 6-8 Expression of survivin is typically limited to developing 
tissues but becomes reactivated in adult tissues during the neoplastic transformation, 
contributing to apoptosis evasion and molecular pathways driving unrestricted 
proliferation and angiogenesis in tumor cells.9 Survivin expression is a marker of poor 
prognosis and/or resistance to therapy in multiple cancers.10 In patients with a variety of 
cancers, survivin-specific cell mediated and humoral immune responses have been 
shown.11-14 Preclinical and clinical data from survivin vaccination studies suggest that 
these vaccines can induce immune responses and do not raise substantial safety 
concerns. Multiple HLA class I-binding peptides and one HLA class II-binding peptide of 
survivin have been identified, some of which have demonstrated immunogenicity in 
clinical trials.15, 16 
Malignant mesothelioma (MM) is an aggressive and deadly cancer. It originates from a 
chronic inflammatory process arising from asbestos or erionite exposure. The median 
patient survival is 9-12 months from diagnosis and intervention with trimodality therapy 
(chemotherapy, surgical resection and thoracic radiation) only extends survival by an 
average of 5 months. Survivin overexpression has been reported in MM in different 
studies.17, 18 Our previous work involved the development of a novel recombinant 
fowlpox virus encoding survivin (FP-surv) vaccine that was evaluated for efficacy in 
different MM mouse models. Mice were injected subcutaneously or intraperitoneally with 
murine fiber-induced MM tumor cells and vaccinated with FP-surv. Results showed that 
FP-surv vaccination generated significant immune responses in both models, which led 
to delayed tumor growth and improved animal survival.17 
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We have extended those previous findings in the current study, which involves the pre-
clinical development of an optimized version of FP-surv designed for human 
immunization (HIvax). With the purpose of identifying survivin-derived peptides that are 
highly immunogenic for the most common HLAs in the human population, the survivin 
protein was analyzed using an innovative epitope-prediction algorithm called 
EpiMatrix.19-22 The immunogenicity of the predicted peptides was confirmed in co-
culture experiments using autologous DC and T cells isolated from human healthy 
donors. The sequences encoding peptides, confirmed to induce CTLs activation in 
these co-cultures, were then inserted in a transgene optimized for presentation of 
processed peptides on MHC-I (HIvax1). Similarly, sequences for peptides found to 
activate Th cells were included in a transgene engineered to present antigens on MHC-
II (HIvax2). One of the predicted MHC-I restricted peptides, (survivin 20-28), previously 
reported as an HLA binder,5, 15 did not activate human CTLs in our co-culture 
experiments; hence it was excluded by our vaccine design. Recombinant fowlpox 
vectors expressing the HIvax transgenes were then generated and their efficacy was 
evaluated with subsequent co-culture experiments to measure interferon- (IFN) and 
granzyme B secretion in human CD8+ and CD4+ T lymphocytes isolated from donors 
with different haplotypes. 
 
 
  
D
ow
nl
oa
de
d 
by
 [A
nn
ie 
De
 G
ro
ot 
M
D]
 at
 11
:02
 29
 Ju
ne
 20
15
 
 6 
 
RESULTS 
In silico epitope mapping and peptide selection 
The human survivin protein was computationally screened for class I and class II MHC 
epitopes using EpiMatrix. The protein sequence was parsed into 9-mer sequences, 
each overlapping the next by 8 amino acids, respectively, for a total of 134 9-mers. 
Each of these peptides was then scored for Class I HLA motif matches to the A*0101, 
A*0201, A*0301, A*2402, B*0702 and B*4403 alleles. More than 50 EpiMatrix hits (Z-
score > 1.64; top 5% of scores) were discovered (data not shown). Among these, 4 
sequences, positively scored for the considered alleles, were selected for experimental 
validation (Supplemental table 1). For Class II, epitope dense regions containing 
sequences predicted to bind multiple Class II HLA alleles (DRB1*0101, *0301, *0401, 
*0701, *1101, *1301 and *1501) were also identified. Three of these regions containing 
“hits” for several analyzed alleles were selected and the resulting peptide sequences 
were synthesized for experimental validation (Supplemental table 2). 
 
Human survivin-derived peptides induce activation of primary human CD3+ T cells 
Seven peptides (Hsurv1-7) representing sequences considered immunogenic in a major 
number of alleles were synthesized (Table 1). These EpiMatrix predicted peptides were 
used to prime human DC from naïve healthy donors. Autologous T cells were co-
cultured with the DC for a 2 wks period, followed by reactivation with DC loaded with the 
same peptide in the presence of monensin, to allow evaluation of IFN production. All 
peptides but one (Hsurv4) stimulated a significant number of specific IFN+ CD3+ T 
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lymphocytes in the donors (Figure 1). In contrast, overall responses to Hsurv4 peptide 
did not significantly differ from controls, which consisted of T cells stimulated with 
unpulsed DC (No pep) or irrelevant peptide pulsed DC (Irr pep). These experiments 
were reproduced at least in triplicate in ten healthy donors, each having a different 
haplotype, to assess the efficacy of the peptides in various HLA settings. Data 
representing CD3+ T cell responses to survivin peptides for each individual donor are 
included in Supplemental Table 3.  
 
Selected survivin peptides induce IFN secretion in human CD4+ and CD8+ T cells 
We next evaluated separately the activation of CD3+ T cell subpopulations: CD3+/CD4+ 
T cells and CD3+/CD8+ T cells. Lymphocytes purified from peripheral blood were 
cultured with autologous DC loaded with peptides designed for MHC-II (Hsurv1, 2, or 3) 
or MHC-I presentation (Hsurv4, 5, 6 or 7). IFN production was evaluated by 
intracellular flow cytometric analyses on CD4+ or CD8+ T cells (Fig.2). Percentages of 
IFN+ T cells induced by the survivin peptides were compared with T cells stimulated 
with unpulsed DC (No pep), or with irrelevant peptide pulsed DC (Irr pep). Peptides 
designed for MHC-II presentation (Hsurv1, 2, or 3) activated peptide-specific CD4+ T 
lymphocytes in 90% of donors (Table 2). Peptides designed for MHC-I (Hsurv5, 6 or 7) 
activated CD8+ T lymphocytes responses in 100% of donors. Peptide Hsurv4, an 
antigen reported to induce immune responses in both mice and humans,5, 23, 24 only 
stimulated T cells from a single donor only. Experiments were also performed to confirm 
that T cell responses were not induced by confounding artifacts related to the source of 
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peptide such as salts or buffer contaminants such as endotoxin. Production of IFN in T 
cells were simultaneously evaluated using the peptides described above and Hsurv 
peptides independently synthetized (i.s.) by a second commercial source. In these 
experiments we evaluated CD4+ T cell responses after stimulation with Hsurv2 peptide 
and CD8+ responses after stimulation with Hsurv4 or Hsurv5 compared to Hsurv2 (i.s.), 
Hsurv4 (i.s.) and Hsurv5 (i.s.). Similar CD4+ T cell responses were stimulated by Hsurv2 
and Hsurv2 (i.s.) and also similar CD8+ T cell responses were induced by Hsurv5 and 
Hsurv5 (i.s.). Both Hsurv4 and Hsurv4 (i.s.) did not induce significant CD8+ T cell 
responses (Supplemental Fig.1). These results suggested that the T cell IFN 
responses were elicited by the peptides themselves.   
 
Removal of survivin 20-28 peptide (Hsurv4) from stimulatory peptides leads to 
stronger and more consistent in vitro immunization 
The survivin peptide 20-28, designed Hsurv4 in our experiments, was the only peptide 
selected from the EpiMatrix analysis that did not induce significant CD3+ T cell overall 
responses in our population of naïve human donors. This 9-mer was predicted to bind to 
multiple MHC-I alleles, but it only induced CD8+ T cell activation from one human 
subject out of ten. To better evaluate the contribution of Hsurv4 in a hypothetical setting 
of multi-antigen vaccination, we compared pools of survivin peptides containing Hsurv4 
(Hsurv1-7) to those without it (Hsurv 1,2,3,5,6,7). DC were stimulated with these peptide 
pools and used to prime autologous T cells. Table 3 shows the results of CD4+ and 
CD8+ T cells from four healthy donors with the two different peptide pools. In 75% of the 
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experiments, the pool without Hsurv4 induced CD4+ and CD8+ T cell responses. In 
comparison, the pool Hsurv1-7 that includes all the studied peptides induced both types 
of T cell responses in 50% of the experiments. In cells derived from one of the analyzed 
subjects the inclusion of Hsurv4 in the peptide pool led to lower numbers of IFN-
secreting CD4+ and CD8+ T cells (Supplemental Fig.2). These results, together with 
those obtained using the single Hsurv4 peptide, suggest that the exclusion of this 
epitope may produce better immunization responses in humans. 
 
Development of HIvax1 and HIvax2 and analysis of their expression in human 
primary DC 
We constructed two fowlpox-based DNA vaccines, HIvax1 and HIvax2, each containing 
a distinct set of HLA class I and class II epitopes (Figure 3A). In HIvax1, sequences 
encoding Hsurv5, 6 and 7 were engineered into the vaccine matching the same order in 
which they are presented in the wild-type protein. Spacer sequences (Ala-Ala-Tyr) were 
included to promote the interaction between epitopes and transporters of antigen 
processing (TAP) that facilitate MHC-I loading in the endoplasmic reticulum (ER). 25 To 
further guide the HIvax1 encoded polypeptides to the ER and facilitate MHC-I loading, 
the immunoglobulin K (IgK) leader sequence was positioned upstream of epitope 
sequences, 26 resulting in trafficking of the peptide-MHC-I complex to the cell surface for 
interaction with the T cell receptor (TCR) on CD8+ T cells (Figure 3D). In designing the 
HIvax2 antigen we included the tissue plasminogen activator (tPA) leader sequence 
upstream of epitope sequences to direct translation products to the secretory pathway. 
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The inclusion of Gly-Pro-Gly-Pro-Gly spacers between peptides, avoids the formation of 
immunodominant junctional epitopes.27 In both HIvax1 and HIvax2, V5 tag sequences 
were included at the C-terminus to facilitate polypeptides detection. 
RT-PCR was used to evaluate the expression of HIvax transgenes in mature human DC 
infected with recombinant fowlpox vectors codifying for HIvax1 or HIvax2. Fowlpox 
vectors without the transgenes (FP-ctrl) were used as control. DC infected with HIvax1 
or HIvax2 produced the corresponding mRNA, whereas DC infected with FP-ctrl were 
negative (Fig.3B). The production of the HIvax1 and HIvax2 polypeptides was then 
evaluated through immunofluorescence staining of infected DC using anti-V5tag 
antibodies. Results showed the presence of the polypeptides produced by HIvax1 and 
HIvax2 in the cytoplasm of infected cells  (Fig.3C). 
 
In vitro immunization of human DC with HIvax1 or HIvax2 induces IFN production 
in autologous T cells  
The efficacy of HIvax vaccines in stimulating survivin specific T cells was evaluated 
using immune cells from two naïve healthy donors with different haplotypes (Fig. 4 and 
Supplemental Fig. 3). Monocyte-derived DC were infected with recombinant fowlpox 
vectors encoding HIvax1 or HIvax2, whereas FP-ctrl was used to infect DC in controls. 
Autologous T cells were cultured with the DC for 2 wks and then were reactivated with 
DC loaded with a pool of Hsurv5, 6, 7 peptides for HIvax1 or a pool of Hsurv1, 2, 3 
peptides for HIvax2. In both cases control DC (No pep) were used as controls. Flow 
cytometric analysis revealed that CD8+ T cells stimulated by HIvax1 responded to DC 
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loaded with Hsurv5, 6, 7 by producing IFN (Fig. 4A). In contrast, T cells initially 
incubated with FP-ctrl and reactivated by DC loaded with the same peptides did not 
produce IFN. Immune cells from this specific donor (Table 2, Donor no.5) were used to 
test HIvax2 and results showed that CD4+ T cells stimulated by this vaccine reacted to 
DC loaded with Hsurv1, 2, 3 by producing IFN (Fig. 4B). DC loaded with the same 
peptides did not activate T cells stimulated by FP-ctrl. In immune cells from a donor with 
a different haplotype (Table 2, Donor no.8), HIvax1 induced CD8+ T cells while HIvax2 
did not induce a IFN response. This may reflect differences in immunogenicity of 
HIvax2 epitopes for different MHC-II haplotypes. 
 
T cells activated by HIvax1 and HIvax2 exhibit cytotoxic activity towards MM cells 
In previous studies we demonstrated that human malignant mesothelioma (MM) cells 
express high levels of survivin.17 To further evaluate the efficacy of our HIvax approach, 
experiments were conducted in which survivin overexpressing ADA MM cells were co-
cultured with T cells activated by HIvax vaccines. Both HIvax 1 and 2 vaccines were 
used together to simultaneously activate both CD4+ and CD8+ T cells and thereby 
increase the cytotoxic potential of CTLs. T cells stimulated with HIvax or with the control 
vaccine FP-ctrl were also assayed versus survivin-negative, primary autologous skin 
fibroblasts. To evaluate the cytotoxic activity of CTLs against MM cells or fibroblasts, 
secretion of granzyme B was measured by ELISPOT. Significantly higher granzyme B 
was detected for T cells activated by HIvax, co-cultured with ADA MM cells, but not with 
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primary fibroblasts (Fig.5). Altogether, these results suggest specific CTL function 
against MM generated by HIvax. 
DISCUSSION 
In this study we describe the development of novel multi-epitope vaccines (HIvax1 and 
HIvax2) specifically designed to induce anti-tumor immune responses for eventual use 
in clinical trials. These data were built upon our previously published work 
demonstrating that fowlpox vectors expressing full-length survivin were capable of 
activating T cell responses against MM cells in mice. Full tumor regression was induced 
in a significant number of vaccinated mice, even if some mice retained MM tumors.17 It 
has been recently demonstrated that human “self” proteins may contain regulatory T cell 
epitopes. These sequences (tregitopes) activate T regulatory cells and lead to the 
suppression of CD4+ and CD8+ T cell responses. Therefore, the efficacy of vaccines 
expressing entire human antigens may be limited by the presence of immune-
suppressive tregitopes that counteract the effects of the other immune-stimulatory 
epitopes.28-30 Our current study was designed to construct vaccines containing only 
stimulatory epitopes by testing the immunogenicity of candidate peptides with DC and T 
cells co-culture experiments. A sophisticated algorithm (EpiMatrix) identified three 
potential MHC-II-binding peptides (Hsurv1, 2, 3) and four potential MHC-I-binding 
peptides (Hsurv4, 5, 6, 7). Multiple experiments were conducted using immune cells 
isolated from ten healthy naïve donors with different haplotypes. All of these peptides, 
with the exception of Hsurv4, induced CD3+ T cell responses as determined by IFN 
production (Fig.1). Analysis of CD3+/CD8+ T cell subpopulations indicated that Hsurv4, 
a peptide predicted to induce CTL responses, was effective in cells from one donor out 
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of ten. The remaining peptides induced CD4+ and CD8+ T cells responses in 50-90% of 
subjects (Table 2). The survivin peptides used in this study have been identified for their 
potential of binding MHC molecules from the most common human HLA alleles 
(Supplemental tables 1 and 2). Analyses of the donors showed that most haplotypes 
belonged to these common HLA alleles. Some less common alleles were present in 
certain donors, but comparisons between EpiMatrix predictions and effective T cell 
responses only included donors with common HLA alleles. Although the sample size 
was too small to draw any definitive conclusion, a qualitative assessment of EpiMatrix 
predictions and observed effective T cell responses suggested that Hsurv4 peptide, 
corresponding to the epitope 20-28 of survivin, may represent an immune-regulatory T 
epitope. Our experiments using peptide pools with or without Hsurv4 suggested that 
often, although not always, the exclusion of this peptide from vaccines may lead to 
stronger IFN responses. However, further evaluation of CD4+ CD25+ FOXp3+ regulatory 
T cells in these experiments did not reveal significant tregitope properties of Hsurv4 
(data not shown).  
Despite an insufficient number of donors in this study is to define the immunostimulatory 
vs. immunosuppressive nature of Hsurv4 (survivin 20-28), the data obtained in our initial 
experiments warranted exclusion of Hsurv4 from the HIvax1. Since suppressive 
epitopes are likely present in full-length antigens, the efficacy of the candidate peptides 
should be evaluated by in vitro immunization studies prior to vaccine production. Ideally, 
personalized vaccine development tailored to include only those peptides found to be 
immunostimulatory for a particular patient would allow vaccines optimized for individuals. 
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In designing HIvax1, MHC-I peptides were separated by Ala-Ala-Tyr spacers and 
targeted to the ER by including an IgK signal sequence. This strategy drives the correct 
presentation of 9-mer peptides in the groove of MHC-I and has been successfully used 
in several vaccine studies.25, 31 For HIvax2, epitopes were instead separated by Gly-
Pro-Gly-Pro-Gly spacers and fused with a plasminogen activator signal sequence (tPA) 
to promote their presentation on MHC-II. Expression of the HIvax2 transgene should 
result in a polypeptide that is secreted, subsequently re-engulfed, and degraded through 
exogenous antigen processing pathways within lysosomes. Resultant peptides are 
loaded into the grooves of MHC-II and transported to the plasma membrane for 
presentation to CD4+ T cells. In addition, the HIvax2 peptides may be also be loaded 
into MHC-I through cross-presentation pathways.21, 22 In brief, prematurely truncated or 
abnormally folded proteins are exported to the cytosol, processed by the proteasome 
and resultant peptides loaded on MHC-I in the ER (Fig. 3). This pathway may also be 
involved in presentation of HIvax1 epitopes to MHC-II as previously demonstrated. 32-34 
The synthetic transgenes used in this study were cloned in recombinant FP vectors. 
Vaccines based on recombinant vectors like FP induce a strong inflammatory response, 
directed mainly towards the vector-encoded proteins. Pox viral vectors are among the 
most heavily exploited in vaccine development,17 and FP has shown particularly 
promising results as a vaccine for infectious diseases and cancer.35 FP infection leads 
to effective antigen presentation by human antigen presenting cells, and the generation 
of antigen-specific CTLs.36 An advantage of FP for vaccination is the fact that this virus 
does not productively replicate in mammalian cells, but still leads to effective expression 
of epitopes as supported by the current study. 
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Since DC represent the most effective antigen presenting cells, this study used human 
monocyte-derived DC infected with HIvax vaccines to confirm the production of mRNA 
and proteins encoded by HIvax transgenes and presentation of antigens to cognate T 
cells. Infected DC from two different donors were used to prime autologous T cells. In 
these experiments, both antigen specific CD4+ and CD8+ T cells were activated in one 
of the two donors, while the other donor displayed only the activation of CD8+ T cells by 
HIvax1. While it is not entirely clear why the differences were found between these two 
individuals, some evidence from the data involving the latter individual's IFN+ CD4+ T 
cells measured after incubation with DC loaded with MHC-II peptides. In particular, this 
last donor presented immune responses for 1 peptide out of 3 as shown in Table 2, 
(Donor no. 8). In comparison, the first donor, for which HIvax2 activated a significant 
number of IFN+ CD4+ T cells, had responses for all 3 Hsurv peptides (Donor no. 5). T 
cells, isolated from this donor, were stimulated using DC infected with both HIvax 
vaccines and evaluated for their cytotoxic ability against MM cells. These cancer cells 
over-express survivin and represent targets for HIvax-stimulated T cells that recognize 
survivin peptides within MHC-I and initiate a cytotoxic activity with secretion of 
granzyme B. Importantly, this vaccination does not promote CTL activity against healthy 
cells as supported by our data showing that T cells stimulated by HIvax were not 
activated by the co-culture with autologous fibroblasts. Taken together, these results 
suggest that HIvax vaccines induce specific CD4+ and CD8+ T cell responses in 
humans and promote specific killing of MM tumor cells in vitro. These activated 
lymphocytes should not induce autoimmune responses in humans since their reactivity 
was evaluated as not significant against autologous “self” cells.  
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These studies provide a rationale and framework for clinical testing of HIvax1 and 
HIvax2 vaccines in patients with survivin-expressing cancers. To understand whether 
patients with MM or other solid tumors will have the capacity to respond to vaccination 
in a manner similar to that seen in vitro with healthy donor cells, further clinically based 
investigations are required.  
MATERIALS AND METHODS 
Epitope selection and peptide synthesis 
Survivin epitopes were scored for binding affinity, across a range of common HLA, 
using the EpiMatrix algorithm.37 Top-scoring sequences were synthesized as 9 mer 
peptides for presentation on MHC-I, and as 15-18 mer for MHC-II (Table I). Synthetic 
peptides were manufactured by Peptide 2.0 (Chantilly, VA) or Elim Biopharm (Hayward, 
CA) using fluo-renylmethoxycarbonyl chemistry and solid-phase synthesis and purified 
by high-pressure liquid chromatography. The quality of the peptides was assessed by 
high-performance liquid chromatography analysis. Peptide purity was >90% as 
ascertained by analytical reversed phase HPLC. Individual peptides were dissolved in 
PBS and used at a final concentration of 10 µg/ml. The following irrelevant control 
peptides were used: eGFP peptide (aa. 200–208) for MHC- I and LCMV peptide (aa. 
61-80) for MHC- II. 
 
Mesothelioma cell line and primary cells 
The human MM cell line ADA was characterized and generously provided by Dr. H. 
Pass.38 ADA cells were cultured in Ham’s F12 culture medium containing 10% FBS and 
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penicillin-streptomycin. Whole blood was drawn from healthy volunteers who gave 
informed consent according to our protocol approved by the University Hawaii 
Committee on Human Subjects Institutional Review Board (CHS#19442). Peripheral 
blood mononuclear cells (PBMC) from these HLA-typed healthy donors were obtained 
by Ficoll density centrifugation.  
In vitro immunization and human T cell cultures. 
To generate monocyte-derived dendritic cells (DC) from PBMCs, adherent cells were 
cultured for 7 days in X-VIVO 15 (Lonza, #04-744Q) containing 500 units/mL 
recombinant human interleukin 4 (IL-4) and 1,000 units/mL recombinant human 
granulocyte macrophage colony-stimulating factor (GM-CSF) (both from BioLegend, 
#574002 and #572902). On days 2 and 5 of incubation, media was replaced with fresh 
medium with IL-4 and GM-CSF. The mature DC expressed associated antigens, such 
as CD80, CD83, CD86, and HLA class I and class II, on their cell surfaces as confirmed 
by flow cytometry (data not shown). On day 5, DC were incubated with one of these 
conditions: 1) with 10 g/mL individual peptides for 48 h; 2) with 10 g/mL of a mixture 
of different peptides for 48 h; 3) with 107 p.f.u./mL recombinant fowlpox vectors for 2 h. 
On day 6, 10 ng/mL tumor necrosis factor  (TNF) (BioLegend, #570102) was added. 
On day 7, T cells were isolated from PBMCs from the same donors using plastic 
adherence to remove monocytes and magnetic anti-CD19 beads (Miltenyi, #130-050-
301) to remove B cells. Purified T cells were incubated at a 100:1 ratio with the DC for 1 
wk, then for another wk in the presence of X-VIVO 15 with 500 units/mL IL-2 
(BioLegend, #589102). On day 14, T cells were plated with freshly isolated and matured 
DC and stimulated for 1 wk in the same conditions. On day 21, T cells were stimulated 
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in presence of monensin (eBioscience, #00-4505-51) with matured DC previously 
loaded with: 1) 10 g/mL individual peptides or 2) 10 g/mL of a mixture of different 
peptides. After 7 h, IFN production of these cells was analysed using a flow cytometer. 
 
Flow cytometric analysis for intracellular IFN-γ 
T cells were stained with the following monoclonal antibodies (mAb): PE/Cy5 
conjugated anti-human CD3 (BioLegend, #300410) mAb, APC conjugated anti-human 
CD4 (BioLegend, #344613) and anti-human CD8 (BioLegend, #344721) mAb, washed 
and treated with a fixation/permeabilization kit (Life technologies, #GAS003). Following 
washes the cells were incubated with Pycoerythrin (PE) conjugated anti-human IFN 
(BioLegend, #506506) mAb. To discriminate between live and dead cells a LIVE/DEAD 
staining kit (Life technologies, #L-34975) was used. Data (300,000 events/sample) were 
collected using the FACScalibur flow cytometer (BD Biosciences, San Jose, CA) and 
analyzed using FlowJo software (Treestar, Ashland, OR). In each experiment, the gate 
for background IFN-producing cells was set in no-peptide control samples at ≤ 0.02%. 
Events registering above this threshold value in peptide-stimulated samples were 
considered “positive” and indicated in data tables as “+”  (> background); or “++” (two 
times > background); or “+++”, (three times > background). 
 
HIvax vaccines engineering 
D
ow
nl
oa
de
d 
by
 [A
nn
ie 
De
 G
ro
ot 
M
D]
 at
 11
:02
 29
 Ju
ne
 20
15
 
 19 
 
Epitope sequences were concatenated to form two multi-epitope genes: HIvax1, 
containing HLA Class I epitopes, and HIvax2, containing HLA Class II epitopes (Fig. 3A). 
All the peptides encoded by these two DNA vaccines were identified by 
immunoinformatics methods and their immunogenicity confirmed with the in vitro 
immunization experiments described above. To avoid creation of novel epitopes at 
epitope junctions, an algorithm which iteratively re-orders epitopes to reduce junctional 
immunogenicity (VaccineCAD), was used to optimize epitope order 21. In addition, 
where re-ordering by VaccineCAD did not sufficiently reduce potential junctional 
immunogenicity, spacer sequences (Ala-Ala-Tyr for HIvax1, and Gly-Pro-Gly-Pro-Gly for 
HIvax2) were engineered between some epitopes to optimize antigen presentation. A 
Kozak sequence was positioned upstream of the coding sequence for efficient 
translation initiation. In HIvax1, to target the peptides to the MHC-I processing pathway, 
the immunoglobulin K (IgK) leader sequence (MGWSCIILFLVATATGVHS) was placed 
upstream of epitope sequences. In HIvax2, to target the immunogens to the MHC-II 
processing pathway, the tissue plasminogen activator (tPA) leader sequence 
(MQMSPALTCLVLGLALVFGEGSA) was placed upstream of epitope sequences to 
direct translation products to the secretory pathway. A V5 tag was incorporated 
downstream of both epitope sequences followed by two stop codons. Genes were 
synthesized by GeneScript (Piscataway, NJ) and cloned into a cassette coding for 
enhanced GFP (eGFP) in the fowlpox Transfer Plasmid Green (TPG) 39, 40. Two 
recombinant fowlpox vectors, expressing the two transgenes, were then generated as 
described previously.17 
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Immunofluorescence  
Mature DC infected with FP-ctrl, HIvax1 or HIvax2 were cultured in culture slides 
(Falcon, #354104). Two days after infection, cells were fixed with methanol, blocked 
with 0.2% gelatin and incubated overnight at 4°C with 1:100 mouse anti-V5 antibodies 
(Santa Cruz Biotechnology, #sc-81594). Slides were then incubated for 2 h with 1:300 
anti-mouse IgG conjugated with Alexa Fluor® 488 (BioLegend, #405319). Expression of 
V5 was evaluated with a Cameleon 3-Channel AOTF LSM confocal microscope (Nikon, 
Melville, NY) in cells counterstained with Propidium Iodide (PI).  
 
Reverse transcription PCR 
Total RNA was extracted from DC infected with FP-ctrl, HIvax1 or HIvax2 using the 
RNeasy™ kit (Qiagen, #75162). RNA samples were treated with 0.05 unit/ml of DNase I 
(Qiagen, #79254) at 20 °C for 15 min. Total RNA (5 μg) was converted into first strand 
cDNA using random hexamers and High Capacity cDNA Synthesis kit (Life 
Technologies, #4368813). The expression of HIvax1 and HIvax2 transgenes was 
detected by PCR using the Taq polymerase kit (Qiagen, # 18038042) in a thermal 
cycler (GeneAmp PCR System 2400, Perkin Elmer, Waltham, MA) followed by agarose 
gel electrophoresis. The sequences of the PCR primers were as follow: HIvax1 forward 
(5’-ATG GGG TGG TCC TGT ATT ATT CTG-3’), HIvax1 reverse (5’-GGC TTG CCC 
TTG TTG TTG GTT TCT-3’), HIvax2 forward (5’-CTG TGC GGA GCC GTG TTC GTC-
3’) and HIvax2 reverse (5’-CTC CAG GGC CAG GTC CAA TCT T-3’). As positive 
controls, 105 p.f.u of HIvax FP vectors were added to the PCR reaction. 
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HLA Typing 
cDNA was generated from RNA samples using Superscript III First-Strand Synthesis 
System for RT-PCR (Life Technologies, # 18080051) with Oligo(dT)20 primer. HLA 
amplicon was created using cDNA amplified with KOD HotStart DNA polymerase (EMD, 
#71086) and fusion primers specially designed for 454 Sequencing analysis. PCR 
products were purified using Agencourt AMPure XP beads (Beckman Coulter, 
#A63880) and quantified using Quant-IT PicoGreen dsAssay kit (Life Technologies, 
#P11496), followed by subsequent normalization and pooling as a preparation for 
emulsion-based clonal amplification PCR (emPCR). The emPCR allows for each strand 
of DNA produced in the HLA-specific PCR to be replicated clonally on a single bead 
using emPCR Reagents and Kit (Roche, Nutley, NJ).  The emulsion mix was aliquoted 
to the wells of a 96-well PCR plate and placed in a Gene Amp PCR Sytem 9700 (Life 
Technologies) and a standard emPCR protocol was carried out over the course of 6 
hours. Beads were then recovered, prepared and individually sequenced using 454 GS 
Junior sequencing system (Roche). 
Sequencing reads were de-multiplexed by sample and trimmed from the adaptor, MID, 
and primer sequences using the Integroomer application 
(http://courge.ics.hawaii.edu/inte/groomer/). The resulting sequences were then 
subtyped through local alignments against the HLA database 41 using the USERCH 
program.42 
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Granzyme B ELISPOT assay 
To measure T cell cytotoxic ability, granzyme B secretion was analyzed using the 
Human Granzyme B ELISpot Kit (R&D system, #EL2906). 105  T cells (effectors), 
stimulated with DC infected with 105 p.f.u. of either FP-ctrl or a mixture of both HIvax 
vaccines, were added in wells followed by 5 X 103 ADA cells or primary skin fibroblasts 
(targets) per well in 100 L. Negative controls consisted of effector cells in the absence 
of target cells, target cells in the absence of effector cells and media only. After 4 h of 
incubation, detection of granzyme B spot was performed following the manufacturer 
directions. Dead T cells we removed with a dead cell removal kit (Miltenyi) before 
incubation with MM cells to enhance specificity. Survivin levels between fibroblast and 
MM cells were detected by western blot using an anti-survivin antibody (Santa Cruz 
Biotechnology, #sc-17779). 
Statistical analyses 
For each blood donor, two experiments have been conducted with each condition 
analyzed in triplicate. All statistical tests were performed using GraphPad Prism 
(GraphPad, La Jolla, CA). Means of two groups were compared using two-tailed 
unpaired Student’s t test. Statistical significance values are indicated in the figures.  
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Table 1. List of survivin peptides evaluated in DC-T cell co-cultures. 
      
Name Epitope Sequence 
Hsurv1 Survivin class II (8-24) acetyl-PAWQPFLKDHRISTFKN-amide 
Hsurv2 Survivin class II (83-97) acetyl-GAAFLSVKKQFEELT-amide 
Hsurv3 Survivin class II (96-113) acetyl-LTLGEFLKLDRERAKNKI-amide 
Hsurv4 Survivin class I (20-28) STFKNWPFL-OH 
Hsurv5 Survivin class I (6-14) LPPAWQPFL-OH 
Hsurv6 Survivin class I (47-55) PTENEPDLA-OH 
Hsurv7 Survivin class I (112-120) KIAKETNNK-OH 
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Table 2. T cell responses after co-culture with DC loaded with Hsurv peptides 
          
              
                  
           
  CD3
+
/CD4
+
 response
A
   CD3
+
/CD8
+
 response
A
 
Donor 
no. HLA A  HLA B  HLA DRB1 
 Hsurv1 Hsurv2 Hsurv3  Hsurv4 Hsurv5 Hsurv6 Hsurv 7 
1  02:01, 11:01 35:01, 13:02 01:01, 07:01 + ++ +  - ++ - - 
2  24:02, 03:01 07:21, 35:01 11:01, 15:01 +++ - +++  - + +++ - 
3  02:01, 03:01 07:02, 35:01 11:03, 15:01 - +++ -  - + - + 
4  68:01, 26:01 35:01, 51:01 11:03, 16:01 - + +  - +++ ++ ++ 
5  01:01, 11:01 08:01, 42:01 03:01, - 
 
++ ++ +  - + + - 
6  29:01, 29:02 35:01, 35:03 11:02, 15:03 +++ - ++  - - + + 
7  02:01, 01:01 07:02, 08:01 03:01, 15:01 - ++ -  - - +++ +++ 
8  03:01, 30:01 13:02, 44:03 04:04, 15:03 ++ - -  - +++ +++ - 
9  11:01, 30:01 13:02, 35:01 04:05, 07:01 + - -  - ++ + ++ 
10  02:01, 33:03 44:03, 15:01 04:01, 07:01 - - -  +++ +++ - + 
              
  60%* 50%* 50%*   10%* 80%* 90%* 70%* 
              
                  
A
 Flow cytometry results comparing T cell reactivity with DC pulsed with stimulating peptide versus autologous not pulsed DC. 
(-), ≤ background; (+),  > background; (++), two times > background; (+++), three times > background.  
  
              
                  
* Percentage of experiments with positive results 
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Table 3. T cell responses after co-culture with DC loaded with Hsurv peptides pools.       
                          
             CD3
+
/CD4
+
 response^   CD3
+
/CD8
+
 response^ 
Donor 
no. HLA A   HLA B   HLA DRB1   Hsurv 1-7 Hsurv 1,2,3,5,6,7   Hsurv 1-7 Hsurv 1,2,3,5,6,7 
1   03:01, 30:01 13:02, 44:03 04:04, 15:03 - +   - + 
2   11:01, 30:01 13:02, 35:01 04:05, 07:01 + +++   + ++ 
3   02:01, 33:03 44:03, 15:01 04:01, 07:01 - +   + - 
4   02:01, 03:01 07:02, 35:01 11:03, 15:01 + -   - + 
                          
                50%* 75%*   50%* 75%* 
                          
                          
A
 Flow cytometry results comparing
 
T cell reactivity with DC pulsed with stimulating peptide pools versus autologous not pulsed DC. 
(-), ≤ background; (+),  > background; (++), two times > background; (+++), three times > background.      
                          
* Percentage of experiments with positive results.             
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FIGURES LEGENDS 
 
Fig. 1. Selected survivin peptides induce production of Interferon  in T cells 
isolated from naïve healthy donors. Blood monocyte-derived dendritic cells (DC), 
cultured from 10 healthy human donors were pulsed with survivin peptides (Hsurv 1-7) 
and used in co-culture experiments with autologous T cells. Intracellular IFN- in T cells 
was evaluated by flow cytometric analyses. (A) Percentages of IFN- expressing CD3+ 
T cells induced by each survivin peptide. DC loaded with an irrelevant peptide or not 
pulsed with any peptide were used to stimulate T cells as controls. Data are presented 
as mean of IFN-+ CD3+ T cells ± S.E., with means from “Hsurv” conditions compared 
with control “No Pep” using a Student’s t-test and significance at *P < 0.05, **P < 0.1. 
(B) Representative data from flow cytometric analysis of IFN- expressing CD3+ T cells. 
T cells were pulsed with DC not loaded (No Pep) or stimulated with Hsurv6 peptide. 
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Fig. 2. Autologous dendritic cells loaded with survivin peptides induce activation 
of CD4+ and CD8+ T cells. Blood monocyte-derived dendritic cells (DC) were pulsed 
with survivin peptides and used in co-culture experiments with autologous T cells. 
Intracellular IFN- in CD4+ and CD8+ T cells was evaluated by flow cytometric analyses. 
(A) Top. Percentages of IFN- expressing CD4+ T cells induced by survivin peptides 
designed for MHC-II (Hsurv 1-3). Donor haplotype: HLA DRB1 11:02, 15:03.  DC loaded 
with an irrelevant peptide or not pulsed with any peptide were used to stimulate T cells 
as controls. Data are presented as mean of IFN-+ CD4+ T cells ± S.E., with means 
compared using a Student’s t-test and significance at *P < 0.05; Bottom. Representative 
data from flow cytometric analysis of IFN- expressing CD4+ T cells. T cells were pulsed 
with DC not loaded (No Pep) or stimulated with Hsurv2 peptide. (B) Top. Percentages of 
IFN- expressing CD8+ T cells induced by survivin peptides designed for MHC-I (Hsurv 
4-7). Donor haplotype: HLA A 68:01, 26:01; HLA B 35:01, 51:01.  Data are presented as 
mean of IFN-+ CD8+ T cells ± S.E., with means compared using a Student’s t-test and 
significance at *P < 0.05; Bottom. Representative data from flow cytometric analysis of 
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IFN- expressing CD8+ T cells. T cells were pulsed with DC not loaded (No Pep) or 
stimulated with Hsurv5 peptide. 
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Fig. 3. Survivin epitopes have been included in HIvax1 e HIvax2. (A) HIvax 1 and 2 
diagrams. Epitopes from Hsurv 5-7 were included in HIvax1, separated by AAY spacers 
and targeted to the ER by including an IgK signal sequence. This strategy facilitates the 
correct presentation of these peptides on MHC-I. For HIvax2, epitopes from Hsurv 1-3 
were separated by GPGPG spacers and fused with a plasminogen activator signal 
D
ow
nl
oa
de
d 
by
 [A
nn
ie 
De
 G
ro
ot 
M
D]
 at
 11
:02
 29
 Ju
ne
 20
15
 
 38 
 
sequence (tPA) to facilitate presentation on MHC-II. (B) Detection of specific RNAs 
produced by DC infected with HIvax. RT-PCR was performed on RNA extracted from 
DC infected with HIvax1 or HIvax2, using primers specific for HIvax1 or HIvax2 
transgenes. Positive control: DNA from HIvax vectors. Negative control: cDNA made 
from RNA from FP-ctrl infected DC. (C) Immunofluorescence staining to detect V5 in 
DC infected with FP-ctrl or HIvax. Fluorochrome-conjugated antibodies were used to 
detect V5 and the cell nuclei counterstained with propidium iodide. (D) Peptides 
produced by HIvax1 and HIvax2 are differentially processed and loaded into MHCs: (1) 
Antigens produced from HIvax1 RNA are processed by ER-resident peptidases and 
peptides mounted on MHC-I. These molecules are then transported to the plasma 
membrane for presentation to CD8+ T cells; (2) Polypeptide encoded by the HIvax2 
transgene is secreted, re-engulfed and degraded in lysosomes. Resultant peptides are 
mounted on MHC-II and transported to the plasma membrane for presentation to CD4+ 
T cells; (3) Prematurely truncated or abnormally folded proteins produced by both 
HIvax1 and HIvax2 are exported to the cytosol, ubiquitinated and processed by the 
proteasome. Resultant peptides are transported back in the ER and loaded on MHC of 
class I. Peptides resulting from proteasome cleavage may be also mounted on MHC of 
class II with a mechanism that does not require TAP or ER transportation. 
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Fig. 4. HIvax1 and HIvax2 induce activation of CD8+ and CD4+ T cells, respectively, 
in a donor with haplotype HLA-A 01:01, 11:01; HLA-B 08:01, 42:01; HLA-DRB1 
03:01. Human dendritic cells (DC) were infected with HIvax1 or HIvax2 and co-cultured 
for 2 wks with autologous T cells. T cells were then pulsed with new DC, not loaded or 
loaded with pool of survivin peptides and evaluated for intracellular IFN- by flow 
cytometric analyses. (A) Top. Percentages of IFN- expressing CD8+ T cells induced by 
DC infected with Fp-ctrl or HIvax1. DC not loaded or loaded with the pool of peptides 
expressed by HIvax1, were used to activate T cells before the analyses. Data are 
presented as mean of IFN-+ CD8+ T cells ± S.E., with means compared using a 
Student’s t-test and significance at *P < 0.05; Bottom. Representative data from flow 
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cytometric analysis of IFN- expressing CD8+ T cells generated with HIvax1. T cells 
were pulsed with DC not loaded or loaded with the pool Hsurv 5,6,7. (B) Top. 
Percentages of IFN- expressing CD4+ T cells induced with Fp-ctrl or HIvax2. DC not 
loaded or loaded with the pool of peptides expressed by HIvax2, were used to pulse T 
cells before the cytometric analyses. Data are presented as mean of IFN-+ CD4+ T 
cells ± S.E., with means compared using a Student’s t-test and significance at *P < 
0.05; Bottom. Representative data from flow cytometric analysis of IFN- expressing 
CD4+ T cells generated with HIvax2. T cells were pulsed with DC not loaded or loaded 
with the pool Hsurv 1,2,3. 
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Fig. 5. Cytolytic potential of HIvax-activated T cells against malignant 
mesothelioma cells overexpressing survivin. (A) ELISPOT analysis of released 
granzyme B was performed after stimulation by DC infected with FP-ctrl or 
HIvax1/HIvax2 simultaneously (HIvax). T cells were co-cultured for 4 h with ADA human 
malignant mesothelioma (MM) cells or primary fibroblasts. Results shown are numbers 
of spots per 104 T cells. Bars correspond to the mean ± S.E. of results obtained from 2 
individual experiments, with means compared using a Student’s t-test and significance 
at *P < 0.05. (B) Western blot analysis of lysates from primary fibroblasts and ADA MM 
cells to detect Survivin. Equal loading was compared using anti-tubulin antibodies. 
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